Aquinox Pharmaceuticals, Inc. (NASDAQ:AQXP) Given “Buy” Rating at Cantor Fitzgerald

Cantor Fitzgerald restated their buy rating on shares of Aquinox Pharmaceuticals, Inc. (NASDAQ:AQXP) in a research note published on Thursday, November 9th. They currently have a $28.00 price target on the stock.

“FDA advisory committee meeting could shed light on FDA views of IC/BPS. On December 7, the FDA will hold an advisory panel (details here) to discuss appropriate patient selection criteria and clinical trial design features, including acceptable endpoints, for demonstrating clinical benefit for drugs” to treat the condition. We believe the meeting could be important to raise awareness of the condition and establish expectations for how IC/BPS drugs should be developed.”,” the firm’s analyst commented.

Other research analysts have also issued research reports about the company. Zacks Investment Research lowered Aquinox Pharmaceuticals from a buy rating to a hold rating in a research report on Tuesday, August 15th. Canaccord Genuity set a $22.00 price target on Aquinox Pharmaceuticals and gave the stock a buy rating in a research report on Tuesday, August 8th. BidaskClub upgraded Aquinox Pharmaceuticals from a sell rating to a hold rating in a research report on Friday, August 4th. Finally, ValuEngine lowered Aquinox Pharmaceuticals from a hold rating to a sell rating in a report on Friday, September 15th. Two analysts have rated the stock with a sell rating, one has issued a hold rating and three have given a buy rating to the stock. The stock has a consensus rating of Hold and an average price target of $22.50.

Shares of Aquinox Pharmaceuticals (NASDAQ:AQXP) traded down $0.08 during midday trading on Thursday, hitting $10.48. The stock had a trading volume of 50,374 shares, compared to its average volume of 86,612. Aquinox Pharmaceuticals has a 1-year low of $10.20 and a 1-year high of $19.97.

COPYRIGHT VIOLATION NOTICE: This report was originally published by BBNS and is the sole property of of BBNS. If you are reading this report on another website, it was illegally stolen and reposted in violation of U.S. & international trademark and copyright legislation. The legal version of this report can be read at https://baseballnewssource.com/markets/cantor-fitzgerald-reiterates-buy-rating-for-aquinox-pharmaceuticals-inc-aqxp/1772061.html.

A number of large investors have recently bought and sold shares of the stock. Alps Advisors Inc. raised its position in Aquinox Pharmaceuticals by 4.7% during the second quarter. Alps Advisors Inc. now owns 21,090 shares of the company’s stock valued at $297,000 after buying an additional 939 shares during the period. Northern Trust Corp grew its stake in Aquinox Pharmaceuticals by 3.3% in the second quarter. Northern Trust Corp now owns 83,207 shares of the company’s stock valued at $1,171,000 after purchasing an additional 2,691 shares in the last quarter. Bank of New York Mellon Corp grew its stake in Aquinox Pharmaceuticals by 16.5% in the second quarter. Bank of New York Mellon Corp now owns 23,260 shares of the company’s stock valued at $327,000 after purchasing an additional 3,299 shares in the last quarter. Alyeska Investment Group L.P. boosted its stake in shares of Aquinox Pharmaceuticals by 1.8% during the 3rd quarter. Alyeska Investment Group L.P. now owns 282,569 shares of the company’s stock worth $4,010,000 after acquiring an additional 5,046 shares in the last quarter. Finally, Archon Partners LLC boosted its stake in shares of Aquinox Pharmaceuticals by 44.0% during the 2nd quarter. Archon Partners LLC now owns 18,000 shares of the company’s stock worth $253,000 after acquiring an additional 5,500 shares in the last quarter. 95.51% of the stock is currently owned by hedge funds and other institutional investors.

Aquinox Pharmaceuticals Company Profile

Aquinox Pharmaceuticals, Inc is a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology. The Company’s primary focus is anti-inflammatory product candidates targeting the Src Homology 2 (SH2)-containing inositol-5-phosphatase 1 (SHIP1) enzyme, which is a regulator of a cellular signaling pathway in immune cells, known as the phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K) pathway.

Receive News & Ratings for Aquinox Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aquinox Pharmaceuticals Inc. and related companies with our FREE daily email newsletter.

 


Latest News

Toronto Blue Jays Launch Internal Investigation on PED Use
Toronto Blue Jays Launch Internal Investigation on PED Use
Seattle Mariners Start Offseason With a Bang: Three Trades Over Four Days
Seattle Mariners Start Offseason With a Bang: Three Trades Over Four Days
MLB Commissioner: New Rule for Pace-of-Play in 2018
MLB Commissioner: New Rule for Pace-of-Play in 2018
Alex Cobb Could Be Good Fit for Cubs
Alex Cobb Could Be Good Fit for Cubs
Joey Votto Is One of Baseball’s Best Hitters
Joey Votto Is One of Baseball’s Best Hitters
Hunter Pence May Become Part-Time Player
Hunter Pence May Become Part-Time Player


Leave a Reply

 
© 2006-2017 BBNS.